Pesquisa de anticorpos znt8 como ferramenta complementar no diagnóstico diferencial entre diabetes autoimune latente do adulto (lada) e diabetes tipo 2
DOI:
https://doi.org/10.51473/rcmos.v1i1.2026.2485Keywords:
LADA; ZnT8; autoanticorpos; diagnóstico diferencial; diabetes autoimune.Abstract
O diabetes autoimune latente do adulto (LADA) é uma forma de diabetes mellitus caracterizada pela presença de autoimunidade contra as células beta pancreáticas, com características intermediárias entre o diabetes mellitus tipo 1 (DM1) e o tipo 2 (DM2). Devido à sua manifestação tardia e à independência inicial em relação à insulinoterapia, o LADA é frequentemente confundido com o DM2, o que dificulta o diagnóstico e o tratamento adequados. Nesse contexto, destaca-se a importância dos marcadores imunológicos, especialmente o anticorpo anti-ZnT8, como ferramenta complementar para o diagnóstico diferencial. Este estudo teve como objetivo analisar a relevância do anticorpo anti-ZnT8 para a identificação de pacientes com LADA. Trata-se de uma revisão integrativa da literatura, realizada com base em artigos científicos publicados em bases de dados nacionais e internacionais. Os estudos analisados demonstraram que o anti-ZnT8 contribui para a detecção de autoimunidade pancreática em indivíduos inicialmente classificados como portadores de DM2, além de estar associado a menor reserva funcional das células beta e a progressão mais rápida para insulinodependência. Conclui-se que o anti-ZnT8 representa um biomarcador promissor para o aprimoramento do diagnóstico diferencial entre LADA e DM2, favorecendo intervenções terapêuticas precoces e um melhor prognóstico clínico.
Downloads
References
POZZILLI, Paolo; PIERALICE, Silvia. Latent Autoimmune Diabetes in Adults. Endocrinology and Metabolism, Seoul, v. 33, n. 2, p. 147–159, 2018.
FADIGA, Lúcia; SARAIVA, Joana; CATARINO, Diana; FRADE, João; MELO, Miguel; PAIVA, Isabel. Adult-onset autoimmune diabetes: comparative analysis of classical and latent presentation. Diabetology & Metabolic Syndrome, Londres, v. 12, n. 1, 2020.
LI, Xia; CHEN, Yan; XIE, Yuting; XIANG, Yufei; YAN, Xiang; HUANG, Gan; ZHOU, Zhiguang. Decline Pattern of Beta-cell Function in Adult-onset Latent Autoimmune Diabetes: an 8-year Prospective Study. The Journal of Clinical Endocrinology & Metabolism, Oxford, v. 105, n. 7, 2020.
RIDNER, Edgardo; YOHENA, Silvana; TORNELLI, Facundo Alejandro; MULLER, Clara; DÍAZ, Silvina; LOVECCHIO, Silvia; FACCINETTI, Natalia Inés; PENAS STEINHARDT, Alberto; VALDEZ, Silvina; GUERRA, Luciano; FRECHTEL, Gustavo. Autoinmunidad contra la célula beta en el adulto mayor con diabetes tipo 2: impacto clínico, metabólico y terapéutico. Revista de la Sociedad Argentina de Diabetes, Buenos Aires, v. 49, n. 3, 2015.
SILKO, Iuliia V.; NIKONOVA, Tatiana V.; IVANOVA, Olga N.; STEPANOVA, Svetlana M.; SHESTAKOVA, Marina V.; DEDOV, Ivan I. Latent autoimmune diabetes of adults (LADA): The informative value of autoantibodies. Terapevticheskii Arkhiv, Moscou, v. 88, n. 10, 2016.
BAUMANN, Katharina; KESSELRING, Katrin; LAMPASONA, Valeria et al. Autoantibodies against zinc transporter 8 further stratify the autoantibody-defined risk for type 1 diabetes in a general population of schoolchildren and exhibit distinctive isoform-binding patterns across different forms of autoimmune diabetes: results from the Karlsburg Type 1 Diabetes Risk Study. Diabetologia, 2020.
MOOSAIE, Fatemeh; MEFTAH, Neda; DERAVI, Niloofar; ABOUHAMZEH, Kosar; DEHGHANI FIROUZABADI, Fatemeh; KHALOO, Pegah; MANSOURNIA, Mohammad Ali; FATEMI ABHARI, Seyede Marzie; NAKHJAVANI, Manouchehr; ESTEGHAMATI, Alireza. Prevalence of diabetes-associated autoantibodies among patients presenting with type 2 diabetes and related metabolic differences. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Auckland, v. 14, p. 3017–3026, 2021.
TRABUCCHI, Aldana; FACCINETTI, Natalia Inés; GUERRA, Luciano L.; PUCHULU, Félix M.; FRECHTEL, Gustavo D.; POSKUS, Edgardo; VALDEZ, Silvina N. Detection and characterization of ZnT8 autoantibodies could help to screen latent autoimmune diabetes in adult-onset patients with type 2 phenotype. Autoimmunity, Londres, v. 45, n. 2, p. 137–142, 2012.
HENEBERG, Petr; ŠIMČÍKOVÁ, Dagmar; ČECHÁKOVÁ, Monika; RYPÁČKOVÁ, Barbora; KUČERA, Petr; ANDĚL, Martin. Autoantibodies against ZnT8 are rare in Central-European LADA patients and absent in MODY patients, including those positive for other autoantibodies. Journal of Diabetes and its Complications, v. 33, n. 11, 2019.
DUNSEATH, Gareth; ANANIEVA-JORDANOVA, Rossitza; COLES, Rebecca; POWELL, Michael; AMOROSO, Marie; FURMANIAK, Jadwiga; REES SMITH, Bernard; DAYAN, Colin; LUZIO, Stephen. Bridging-type enzyme-linked immunoassay for zinc transporter 8 autoantibody measurements in adult patients with diabetes mellitus. Journal of Diabetes Science and Technology, v. 9, n. 4, p. 923–928, 2015.
SILKO, Iuliia V.; NIKONOVA, Tatiana V.; IVANOVA, Olga N.; STEPANOVA, Svetlana M.; SHESTAKOVA, Marina V.; DEDOV, Ivan I. Association of polymorphism rs7903146 gene TCF7L2 with low concentrations of autoantibodies in latent autoimmune diabetes of adults (LADA). Diabetes Mellitus, 2016.
FACCINETTI, Natalia Inés; GUERRA, Luciano; PENAS STEINHARDT, Alberto; IACONO, Ricardo Fernando; FRECHTEL, Gustavo. Characterization of zinc transporter 8 (ZnT8) antibodies in autoimmune diabetic patients from the Argentinian population using monomeric, homodimeric, and heterodimeric ZnT8 antigen variants. Journal of Diabetes Research, Cairo, v. 2016, 2016.
BARRAGÁN-ÁLVAREZ, Claudia Patricia; PADILLA-CAMBEROS, Ernesto; DÍAZ, Norma F.; COTA-CORONADO, Antonio; HERNÁNDEZ-JIMÉNEZ, César. Loss of Znt8 Function in Diabetes Mellitus: Risk or Benefit? Nutrients, Basileia, v. 13, n. 11, 2021.
Published
Issue
Section
Categories
License
Copyright (c) 2026 Isabella Santos Kennd, Dr. Paulo Henrique Rosa Martins (Autor)
This work is licensed under a Creative Commons Attribution 4.0 International License.
This work is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This means you are free to:
- Share — copy and redistribute the material in any medium or format.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
The use of this material is conditioned upon proper attribution to the original author(s), providing a link to the license, and indicating if changes were made. The license does not require permission from the author or the publisher as long as these conditions are met.
The Creative Commons license logo is displayed permanently in the footer of the journal.
The copyright of the manuscript can be retained by the authors without restrictions and can be requested at any time, even after publication in the journal.
How to Cite
